Abnormal NF-κB activation has been implicated in the pathophysiology of COPD [9], thus NF-κB pathway blockers, such as MLN120B, are currently being explored for treatment of inflammatory diseases such as COPD and asthma [10]. Here, NFKB1 is linked to asthma.